Alves Lísia Daltro Borges, de Melo Andreia Cristina, de Lima Araujo Luiz Henrique, Thiago Leandro Souza, Dos Santos Guimarães Isabella, Fernandes Priscila Valverde, Rodrigues Elizangela Marques, Dias Fernando Luiz, Antunes Héliton Spindola, Eisenberg Ana Lucia Amaral, Cohen Goldemberg Daniel
Dentistry Section, National Cancer Institute of Brazil, Rio de Janeiro, Brazil.
Clinical Research Division, National Cancer Institute of Brazil, Rio de Janeiro, Brazil.
Oral Oncol. 2021 Jun;117:105198. doi: 10.1016/j.oraloncology.2021.105198. Epub 2021 Feb 9.
This study aim was to review cases of acinic cell carcinoma (the main differential diagnosis of secretory carcinoma) that were diagnosed and treated at the National Cancer Institute of Brazil (INCA) between 1996 and 2016. The primary objective was to identify underdiagnosed cases of secretory carcinoma via a clinical, immunopathological and molecular reassessment.
This is a cross sectional study, with retrospective data collection from medical records and histological specimen review, with staining for periodic acid-Schiff (PAS) and PAS with diastase, immunohistochemistry for S-100, mammaglobin, and DOG-1, and droplet digital RT-PCR for ETV6-NTRK3. The Research Ethics Committee approved this study, and the patients allowed their participation through informed consent.
Eighty-three cases of acinic cell carcinoma were diagnosed and treated in the specified period at INCA, of which, seven had their diagnosis changed to secretory carcinoma.
The present study adds seven cases of secretory carcinoma to the literature, contributing to a better understanding of the epidemiological, histological, immunohistochemical and molecular characteristics of this recently described tumor. Also, the use of a comprehensive diagnostic approach, including immunohistochemical and molecular methods, along with classical morphological studies, allowed the reclassification of acinic cell carcinoma to secretory carcinoma.
本研究旨在回顾1996年至2016年间在巴西国家癌症研究所(INCA)诊断和治疗的腺泡细胞癌(分泌性癌的主要鉴别诊断)病例。主要目的是通过临床、免疫病理和分子重新评估来识别分泌性癌的诊断不足病例。
这是一项横断面研究,通过回顾病历和组织学标本进行回顾性数据收集,进行过碘酸希夫(PAS)染色及PAS淀粉酶消化染色、S-100、乳腺珠蛋白和DOG-1免疫组化,以及ETV6-NTRK3的液滴数字逆转录聚合酶链反应(RT-PCR)。研究伦理委员会批准了本研究,患者通过知情同意允许参与。
在指定时期,INCA诊断并治疗了83例腺泡细胞癌,其中7例诊断改为分泌性癌。
本研究为文献增添了7例分泌性癌病例,有助于更好地了解这种最近描述的肿瘤的流行病学、组织学、免疫组化和分子特征。此外,使用包括免疫组化和分子方法在内的综合诊断方法,以及经典的形态学研究,使得腺泡细胞癌能够重新分类为分泌性癌。